ZURICH, Oct 28 (Reuters) – Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Real Madrid apologises to Chinese people for Mbappe's Mao 'dictator' comment
VIDEO SHOWS: ARCHIVE SHOTS OF REAL MADRID STADIUM SANTIAGO BERNABEU, KYLIAN MBAPPE, PRESIDENT FLORENTINO PEREZ AND…
BRIEF-Avensia Q3 Revenue SEK 90.3 Mln
Oct 28 (Reuters) - Avensia AB: * Q3 REVENUE UP 1.5% TO 90.3 MSEK *…
Nevada unions, politicians caught between AI job creation and destruction
Oct 28 (Reuters) - On more than 100,000 acres of Nevada desert east of Reno,…
